Last reviewed · How we verify

NCT04382534

A Cross-sectional and Cohort Study of COVID-19 Patients With Post - Discharge Dysfunction

Status unknown Last updated 11 May 2020
What this trial tests

trial testing Respiratory rehabilitation in Covid19 in 300 participants. Status unknown.

Timeline
10 March 2020
Primary endpoint
30 September 2020
31 December 2020

Quick facts

Lead sponsorPeking University Third Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment300
Start date10 March 2020
Primary completion30 September 2020
Estimated completion31 December 2020
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Peking University Third Hospital

Who can join

Adults 18 to 80, any sex, with Covid19 or Respiratory Rehabilitation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Post-discharge rehabilitation regimens for covid-19 patients have not been supported by high-quality evidence-based medical evidence.The first part of this study is a cross-sectional study.The contents of the study were the factors related to the dysfunction of COVID - 19 patients after discharge from the hospital in Wuhan.The second part of this study is a cohort study.To observe the functional changes of COVID-19 patients after discharge in hospital rehabilitation, home rehabilitation and no rehabilitation, in order to propose a more safe and effective rehabilitation program.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Respiratory rehabilitation

Trials testing the same drug.

Other recruiting trials for Covid19

Currently open trials in the same condition.

Other Peking University Third Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04382534.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing